PRODUCT LITERATURE
Efectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial
Although the number of antihyperglycemic agents has expanded signifcantly, sulfonylureas (in particular gliclazide) remain an important option because of a variety of patient and health system factors. The large, real world, observational, and international EASYDia trial evaluated the efectiveness of gliclazide modifed release (MR) 60 mg in individuals with type 2 diabetes with a broad range of diabetes history, body mass index (BMI) and background antihyperglycemic treatment
No other version available